Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 8900 results

  1. Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12157]

    Awaiting development Reference number: GID-TA11717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]

    Awaiting development Reference number: GID-TA11490 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Awaiting development Reference number: GID-TA10961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595]

    Awaiting development Reference number: GID-TA11558 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development

  6. Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]

    Awaiting development Reference number: GID-TA11623 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  9. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Psoriasis: assessment and management (CG153)

    In development Reference number: GID-NG10448 Expected publication date: TBC

    NICE guideline
    In development

  12. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]

    Awaiting development Reference number: GID-TA11792 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [TSID12036]

    Awaiting development Reference number: GID-TA11596 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305]

    In development Reference number: GID-TA11229 Expected publication date: TBC

    Technology appraisal guidance
    In development